ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)

Phase 1/2 Withdrawn University of Pennsylvania

RandomizedParallel-groupDouble-blindPrevention

Summary

A randomized double-blind, placebo controlled clinical trial of the safety, tolerability, and antiviral activity of angiotensin-converting enzyme 2 (ACE2) chewing gum over a 3-day period in non-hospitalized subjects with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.

Timeline

Start: 2025-02
Primary completion: 2025-04-01
Completion: 2025-04-01

Outcome

Outcome not reported

Stopped: “For administrative reasons, the study was never opened and was terminated.”

Publications

Ganesan PK, Kulchar RJ, Kaznica P, Montoya-Lopez R, Green BJ, Streatfield SJ, Daniell H. Optimization of biomass and target protein yield for Phase III clinical trial to evaluate Angiotensin Converting Enzyme 2 expressed in lettuce chloroplasts to reduce SARS-CoV-2 infection and transmission. Plant Biotechnol J. 2023 Feb;21(2):244-246. doi: 10.1111/pbi.13954. Epub 2022 Dec 1. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CTB-ACE2	Protein / enzyme biologic	—	Oral